✦ LIBER ✦

5080 Safety and tolerability of fulvestrant high-dose (500 mg) in postmenopausal women with hormone receptor positive advanced breast cancer

✍ Scribed by N. Gottschalk; I. Kuter; J.F. Robertson; M.J. Ellis; J. Lindeman; I. Schrader; B. Gerber; S.D. Costa; N. Harbeck

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effectiveness and Tolerability of Fulves

✍ Stephen E. Jones; John Pippen 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 112 KB

Results of the CONFIRM Phase III Trial C

✍ Jordan, V.C. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Pharmacokinetic Profile of the Fulvestra

✍ Peter McCormack; Francisco Sapunar 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 266 KB

0185 High-dose fulvestrant (500 mg): Cli

✍ N. Harbeck; I. Kuter; D. Amakye; J.F.R. Robertson; M.J. Ellis 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 52 KB

NEWEST: a Phase II, randomised, neoadjuv

✍ C. Singer; I. Kuter; R. Hegg; R. Badwe; N. Harbeck; J. Bines; E. Lowe 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 63 KB

5072 Independent central review of clini

✍ J.P.O. Lindemann; J.F.R. Robertson; M.J. Ellis; Y. Menu; E.J. Macpherson; D.D.C. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB